Olumiant
(baricitinib) Eli Lilly

Composition:
• Available in film-coated tablet with each contains 2 mg or 4 mg baricitinib

Indications:
• Newly indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy

• Also indicated as monotherapy or in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.